The compelling ACR-368 response rate in a high-unmet-need cancer subtype could support accelerated regulatory pathways. Upcoming data readouts in mid-2026 from Arm 3 and Arm 4 may serve as key catalysts for value inflection. ACR-2316's novel activity in lung cancer expands the platform's validation.
Price Chart
Executive Summary
Acrivon Therapeutics reported financial results for Q4 and full year 2025, showing reduced net losses compared to the prior year, alongside strong clinical data from its ACR-368 trial in serous endometrial cancer with a 52% confirmed overall response rate. The company also advanced its pipeline, including new trial arms for ACR-368 and initial clinical activity for ACR-2316 in lung cancer, while maintaining a cash runway into Q2 2027.
Key Financial Metrics
Key Facts
- ACR-368 showed a 52% confirmed overall response rate (cORR) in serous endometrial cancer (N=23), a high-mortality subtype.
- Net loss improved year-over-year: $19.0M in Q4 2025 vs. $22.8M in Q4 2024; full-year net loss decreased to $77.9M from $80.6M.
- Cash, cash equivalents, and marketable securities totaled $118.6 million as of December 31, 2025, sufficient to fund operations into Q2 2027.
- Initiated Arm 3 and planned Arm 4 in the Phase 2b trial of ACR-368, expanding into biomarker-unselected serous EC patients.
- ACR-2316 showed early clinical activity with tumor shrinkage in SCLC and NSCLC, tumor types not previously responsive to WEE1/PKMYT1 inhibitors.
Financial Impact
Reduced R&D and G&A spending led to lower net losses despite lower interest income. Cash position remains strong at $118.6M.
Risk Factors
- Clinical trial results are interim and based on small sample sizes (e.g., N=23 for serous EC).
- Future funding will require additional capital raises or partnerships, leading to potential dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258877 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 13w ago | Press Release | $1.68 $1.76 | ▲ +4.76% | ▲ +1.50% | $1.73 (+2.98%) |
May 22, 2026 22w ago | DEFA14A | $1.67 $2.39 | ▲ +43.11% | ▲ +40.39% | $1.73 (+3.59%) |
Apr 30, 2026 25w ago | DEFA14A | $1.85 $1.56 | ▼ −15.68% | ▼ −18.78% | $1.73 (−6.49%) |
Mar 19, 2026 31w ago | Press Release | $1.70 $1.52 | ▼ −10.59% | ▼ −24.93% | $1.73 (+1.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers